News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
715,634 Results
Type
Article (43064)
Company Profile (437)
Press Release (672133)
Multimedia
Podcasts (79)
Webinars (13)
Section
Business (209038)
Career Advice (2022)
Deals (36087)
Drug Delivery (106)
Drug Development (84364)
Employer Resources (173)
FDA (16542)
Job Trends (15116)
News (354022)
Policy (33195)
Tag
2024 BioCapital Digital (10)
2024 BioForest Digital (2)
2024 BioForest Standard (1)
2024 BioMidwest Digital (9)
2024 BioMidwest Standard (1)
2024 Bio NC Digital (8)
2024 Bio NC Standard (1)
2024 Biotech Bay Standard (18)
2024 Biotech Beach Digital (10)
2024 Biotech Beach Standard (5)
2024 Genetown Digital (9)
2024 Genetown Standard (9)
2024 Lone Star Bio Digital (8)
2024 Pharm Country Digital (7)
2024 Pharm Country Standard (5)
2025 BioForest Digital (4)
2025 Lone Star Bio Digital (8)
2026 BioCapital Standard (1)
2026 BioMidwest Elite (2)
2026 Bio NC Standard (1)
2026 Biotech Bay Elite (1)
2026 Biotech Bay Standard (1)
2026 Biotech Beach Elite (2)
2026 Genetown Elite (3)
2026 Genetown Standard (1)
2026 Pharm Country Elite (1)
2026 Pharm Country Standard (2)
Academia (2658)
Accelerated approval (6)
Adcomms (26)
Allergies (85)
Alliances (51099)
ALS (92)
Alzheimer's disease (1424)
Antibody-drug conjugate (ADC) (132)
Approvals (16527)
Artificial intelligence (258)
Autoimmune disease (24)
Automation (15)
Bankruptcy (373)
Best Places to Work (11857)
BIOSECURE Act (19)
Biosimilars (107)
Biotechnology (330)
Bladder cancer (67)
Brain cancer (27)
Breast cancer (276)
Cancer (2176)
Cardiovascular disease (185)
Career advice (1688)
Career pathing (29)
CAR-T (152)
Cell therapy (428)
Cervical cancer (20)
Clinical research (68308)
Collaboration (843)
Compensation (523)
Complete response letters (24)
COVID-19 (2649)
CRISPR (42)
C-suite (235)
Cystic fibrosis (105)
Data (2085)
Decentralized trials (2)
Denatured (27)
Depression (47)
Diabetes (263)
Diagnostics (6421)
Digital health (19)
Diversity (8)
Diversity, equity & inclusion (44)
Drug discovery (124)
Drug pricing (106)
Drug shortages (26)
Duchenne muscular dystrophy (98)
Earnings (87659)
Editorial (40)
Employer branding (21)
Employer resources (147)
Events (115796)
Executive appointments (712)
FDA (17752)
Featured Employer (54)
Fibrodysplasia Ossificans Progressiva (1)
Friedreich's ataxia (4)
Frontotemporal dementia (8)
Funding (754)
Gene editing (109)
Generative AI (20)
Gene therapy (312)
GLP-1 (747)
Government (4515)
Grass and pollen (4)
Guidances (51)
Healthcare (19168)
Huntington's disease (24)
IgA nephropathy (28)
Immunology and inflammation (126)
Indications (27)
Infectious disease (2792)
Inflammatory bowel disease (143)
Inflation Reduction Act (11)
Influenza (51)
Intellectual property (93)
Interviews (311)
IPO (16815)
IRA (43)
Job creations (3707)
Job search strategy (1435)
Kidney cancer (10)
Labor market (36)
Layoffs (496)
Leadership (17)
Legal (7997)
Liver cancer (75)
Lung cancer (314)
Lymphoma (141)
Machine learning (5)
Management (58)
Manufacturing (292)
MASH (65)
Medical device (13498)
Medtech (13503)
Mergers & acquisitions (19783)
Metabolic disorders (694)
Multiple sclerosis (80)
NASH (19)
Neurodegenerative disease (97)
Neuropsychiatric disorders (30)
Neuroscience (1971)
NextGen: Class of 2025 (6760)
Non-profit (4551)
Northern California (2570)
Now hiring (38)
Obesity (379)
Opinion (225)
Ovarian cancer (76)
Pain (86)
Pancreatic cancer (81)
Parkinson's disease (153)
Partnered (21)
Patents (227)
Patient recruitment (101)
Peanut (48)
People (58645)
Pharmaceutical (87)
Pharmacy benefit managers (19)
Phase I (21437)
Phase II (30104)
Phase III (22317)
Pipeline (1146)
Policy (139)
Postmarket research (2632)
Preclinical (9136)
Press Release (67)
Prostate cancer (103)
Psychedelics (37)
Radiopharmaceuticals (261)
Rare diseases (397)
Real estate (6019)
Recruiting (66)
Regulatory (22778)
Reports (46)
Research institute (2425)
Resumes & cover letters (351)
Rett syndrome (4)
RNA editing (4)
RSV (42)
Schizophrenia (73)
Series A (134)
Series B (87)
Service/supplier (11)
Sickle cell disease (57)
Southern California (2221)
Special edition (17)
Spinal muscular atrophy (152)
Sponsored (29)
Startups (3764)
State (2)
Stomach cancer (16)
Supply chain (66)
Tariffs (24)
The Weekly (50)
United States (22646)
Vaccines (691)
Venture capitalists (40)
Weight loss (253)
Women's health (36)
Worklife (16)
Date
Last 7 days (486)
Last 30 days (2221)
Last 365 days (33921)
2025 (9515)
2024 (36419)
2023 (41131)
2022 (52433)
2021 (56877)
2020 (55018)
2019 (47517)
2018 (35797)
2017 (33189)
2016 (32486)
2015 (38532)
2014 (32328)
2013 (27245)
2012 (29335)
2011 (29974)
2010 (28150)
Location
Africa (737)
Alabama (57)
Alaska (7)
Arizona (238)
Arkansas (14)
Asia (39459)
Australia (6569)
California (5925)
Canada (1953)
China (505)
Colorado (260)
Connecticut (278)
Delaware (137)
Europe (86355)
Florida (875)
Georgia (203)
Idaho (57)
Illinois (532)
India (25)
Indiana (304)
Iowa (10)
Japan (152)
Kansas (105)
Kentucky (24)
Louisiana (10)
Maine (62)
Maryland (878)
Massachusetts (4521)
Michigan (217)
Minnesota (386)
Mississippi (2)
Missouri (80)
Montana (29)
Nebraska (25)
Nevada (60)
New Hampshire (66)
New Jersey (1694)
New Mexico (30)
New York (1676)
North Carolina (1004)
North Dakota (7)
Northern California (2570)
Ohio (197)
Oklahoma (14)
Oregon (37)
Pennsylvania (1328)
Puerto Rico (11)
Rhode Island (31)
South America (1113)
South Carolina (20)
South Dakota (1)
Southern California (2221)
Tennessee (99)
Texas (881)
Utah (175)
Virginia (140)
Washington D.C. (61)
Washington State (552)
West Virginia (3)
Wisconsin (52)
715,634 Results for "inhibitor therapeutics inc".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
GLP-1
GLP-1 Drug Boom Recalls the Rise of PD-1 Checkpoint Inhibitors
The explosion of GLP-1 weight loss drugs is reminiscent of the early days of PD-1 inhibitors, but key market differences suggest history may not repeat itself.
March 19, 2025
·
8 min read
·
Ben Hargreaves
Press Releases
BlossomHill Therapeutics to Present the Design and Discovery of BH-30643, the Company’s OMNI-EGFR™ Inhibitor, at the 2025 AACR Annual Meeting
April 3, 2025
·
3 min read
Press Releases
Vividion Therapeutics Doses First Patient in Phase I Study of RAS-PI3Kα Inhibitor for Treatment of Advanced Solid Tumors
April 3, 2025
·
5 min read
Press Releases
Indaptus Therapeutics Initiates Phase 1 Combination Study of Decoy20 with PD-1 Checkpoint Inhibitor Tislelizumab
March 19, 2025
·
7 min read
Press Releases
Neurocrine Biosciences Presents Real-World Data on Therapeutic Dose Attainment and Dosing Trends of VMAT2 Inhibitors in Patients With Tardive Dyskinesia
April 1, 2025
·
12 min read
Press Releases
Ventus Therapeutics Announces Publication in Nature’s Communications Chemistry Describing the Structure-based Optimization of a New Series of cGAS Inhibitors
March 26, 2025
·
3 min read
News
Jubilant Therapeutics Inc. announces First Patient Dosing in Global Clinical Trials for JBI-802, a CoREST Inhibitor and JBI-778, a PRMT5 Inhibitor
October 25, 2024
·
5 min read
Press Releases
Pliant Therapeutics Announces Interim Phase 1 Data for PLN-101095 in Patients with Immune Checkpoint Inhibitor-Refractory Advanced Solid Tumors
March 17, 2025
·
6 min read
Press Releases
Salarius Pharmaceuticals Merger Partner, Decoy Therapeutics, Announces its Novel Inhibitors Show Promising In Silico Activity Against Measles and Related Viruses
March 27, 2025
·
11 min read
BioCapital
Inhibitor Therapeutics, Inc. Exclusive License with Johns Hopkins University
Inhibitor Therapeutics, Inc. has entered into an exclusive, worldwide licensing agreement with Johns Hopkins University for their U.S Patent 8,980,930 “New Angiogenesis Inhibitors”.
December 13, 2023
·
5 min read
1 of 71,564
Next
